These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 33834412

  • 1. "Novel Psychopharmacology for Depressive Disorders".
    Fornaro M, De Berardis D, Anastasia A, Fusco A.
    Adv Exp Med Biol; 2021; 1305():449-461. PubMed ID: 33834412
    [Abstract] [Full Text] [Related]

  • 2. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.
    Rotroff DM, Corum DG, Motsinger-Reif A, Fiehn O, Bottrel N, Drevets WC, Singh J, Salvadore G, Kaddurah-Daouk R.
    Transl Psychiatry; 2016 Sep 20; 6(9):e894. PubMed ID: 27648916
    [Abstract] [Full Text] [Related]

  • 3. An update on NMDA antagonists in depression.
    Pochwat B, Nowak G, Szewczyk B.
    Expert Rev Neurother; 2019 Nov 20; 19(11):1055-1067. PubMed ID: 31328587
    [Abstract] [Full Text] [Related]

  • 4. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K.
    Psychiatry Clin Neurosci; 2019 Oct 20; 73(10):613-627. PubMed ID: 31215725
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB.
    Am J Psychiatry; 2019 Jun 01; 176(6):428-438. PubMed ID: 31109201
    [Abstract] [Full Text] [Related]

  • 6. Ketamine in the Treatment of Depressive Episodes.
    Ritter P, Findeis H, Bauer M.
    Pharmacopsychiatry; 2020 Mar 01; 53(2):45-50. PubMed ID: 31434140
    [Abstract] [Full Text] [Related]

  • 7. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
    Kokane SS, Armant RJ, Bolaños-Guzmán CA, Perrotti LI.
    Behav Brain Res; 2020 Apr 20; 384():112548. PubMed ID: 32061748
    [Abstract] [Full Text] [Related]

  • 8. Ketamine: The final frontier or another depressing end?
    Sial OK, Parise EM, Parise LF, Gnecco T, Bolaños-Guzmán CA.
    Behav Brain Res; 2020 Apr 06; 383():112508. PubMed ID: 32017978
    [Abstract] [Full Text] [Related]

  • 9. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R.
    Rev Invest Clin; 2018 Apr 06; 70(2):65-7. PubMed ID: 29718013
    [Abstract] [Full Text] [Related]

  • 10. Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
    Lengvenyte A, Strumila R, Olié E, Courtet P.
    Eur Neuropsychopharmacol; 2022 Apr 06; 57():88-104. PubMed ID: 35219097
    [Abstract] [Full Text] [Related]

  • 11. Glutamate-based antidepressants: preclinical psychopharmacology.
    Pilc A, Wierońska JM, Skolnick P.
    Biol Psychiatry; 2013 Jun 15; 73(12):1125-32. PubMed ID: 23453290
    [Abstract] [Full Text] [Related]

  • 12. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
    DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV.
    Ann N Y Acad Sci; 2015 May 15; 1345(1):47-58. PubMed ID: 25649308
    [Abstract] [Full Text] [Related]

  • 13. Ketamine and the next generation of antidepressants with a rapid onset of action.
    Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA.
    Pharmacol Ther; 2009 Aug 15; 123(2):143-50. PubMed ID: 19397926
    [Abstract] [Full Text] [Related]

  • 14. Targeting glutamate signalling in depression: progress and prospects.
    Murrough JW, Abdallah CG, Mathew SJ.
    Nat Rev Drug Discov; 2017 Jul 15; 16(7):472-486. PubMed ID: 28303025
    [Abstract] [Full Text] [Related]

  • 15. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
    Ghasemi M, Kazemi MH, Yoosefi A, Ghasemi A, Paragomi P, Amini H, Afzali MH.
    Psychiatry Res; 2014 Feb 28; 215(2):355-61. PubMed ID: 24374115
    [Abstract] [Full Text] [Related]

  • 16. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
    Abdallah CG, Sanacora G, Duman RS, Krystal JH.
    Annu Rev Med; 2015 Feb 28; 66():509-23. PubMed ID: 25341010
    [Abstract] [Full Text] [Related]

  • 17. Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk.
    Nikayin S, Sanacora G.
    CNS Drugs; 2021 Oct 28; 35(10):1069-1079. PubMed ID: 34491545
    [Abstract] [Full Text] [Related]

  • 18. A letter to the editor, associated with the article entitled "Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketamine vs lithium" by Vázquez et al. (Journal of Psychopharmacology, 2021, Vol. 35(8) 890-900).
    Terao I, Honyashiki M, Inoue T.
    J Psychopharmacol; 2022 May 28; 36(5):653-654. PubMed ID: 35475361
    [No Abstract] [Full Text] [Related]

  • 19. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID, Park LT, Zarate CA.
    CNS Drugs; 2021 May 28; 35(5):527-543. PubMed ID: 33904154
    [Abstract] [Full Text] [Related]

  • 20. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
    Rong C, Park C, Rosenblat JD, Subramaniapillai M, Zuckerman H, Fus D, Lee YL, Pan Z, Brietzke E, Mansur RB, Cha DS, Lui LMW, McIntyre RS.
    Int J Environ Res Public Health; 2018 Apr 17; 15(4):. PubMed ID: 29673146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.